Healthcare
Live Price
Offline$1.83
-3.68% today
1Y Change
+6.48%
Window
Jun 25, 2025 β Jun 23, 2026
Coverage: 249 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Innate Pharma S.A. (IPHA) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $1.83 and up 6.5% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of -77.9%, EPS growth of +13.1%, a dividend yield of 0.0%. What stands out right now is revenue -77.9%, EPS +13.1%, free cash flow -597.2% with operating margin -2058.0% and ROIC -155.5%. Valuation already assumes a fairly strong business story at price/sales 40.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IPHA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IPHA
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IPHA Max Drawdown
-50.84%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Uses the longest available daily history for IPHA and SPY.
Next Step
Earnings pages get much more useful when they are tied back to upcoming dates, expectations, and peer setups.